Evidence map›Paper›PMID 30642353›Full record

ArticleJournal of hematology & oncology2019

Long non-coding RNAs defining major subtypes of B cell precursor acute lymphoblastic leukemia.

Alva Rani James, Michael P Schroeder, Martin Neumann, Lorenz Bastian, Cornelia Eckert, Nicola Gökbuget, Jutta Ortiz Tanchez, Cornelia Schlee, Konstandina Isaakidis, Stefan Schwartz and 12 more

Open access · goldAbstract read
In one paragraph

Article in Journal of hematology & oncology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.

0numbers the graph read from it
0cells of the map it votes in
36citing papers in PubMed
3.1field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

36 citing papers in PubMed, 51 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Review
  6. Age-Driven Genetic and Epigenetic Heterogeneity in B-ALL.International journal of molecular sciences · 2025
    Review
  7. Review
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Underexpression ofFrontiers in oncology · 2022
    Article
  17. Targeting the lncRNA DUXAP8/miR-29a/Frontiers in oncology · 2022
    Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors at 8 institutions in 1 country.

Alva Rani JamesDepartment of Hematology and Oncology, Charité, University Hospital Berlin, Campus Benjamin Franklin, 12203, Berlin, Germany.
Michael P SchroederDepartment of Hematology and Oncology, Charité, University Hospital Berlin, Campus Benjamin Franklin, 12203, Berlin, Germany.
Martin NeumannDepartment of Hematology and Oncology, Charité, University Hospital Berlin, Campus Benjamin Franklin, 12203, Berlin, Germany.
Lorenz BastianDepartment of Hematology and Oncology, Charité, University Hospital Berlin, Campus Benjamin Franklin, 12203, Berlin, Germany.
Cornelia EckertGerman Cancer Research Center (DKFZ), 69120, Heidelberg, Germany.
Nicola GökbugetGerman Cancer Research Center (DKFZ), 69120, Heidelberg, Germany.
Jutta Ortiz TanchezDepartment of Hematology and Oncology, Charité, University Hospital Berlin, Campus Benjamin Franklin, 12203, Berlin, Germany.
Cornelia SchleeDepartment of Hematology and Oncology, Charité, University Hospital Berlin, Campus Benjamin Franklin, 12203, Berlin, Germany.
Konstandina IsaakidisDepartment of Hematology and Oncology, Charité, University Hospital Berlin, Campus Benjamin Franklin, 12203, Berlin, Germany.
Stefan SchwartzDepartment of Hematology and Oncology, Charité, University Hospital Berlin, Campus Benjamin Franklin, 12203, Berlin, Germany.
Thomas BurmeisterDepartment of Hematology, Oncology and Tumor Immunology, Charité University Hospital Berlin, Campus Virchow-Klinikum, 13353, Berlin, Germany.
Arend von StackelbergGerman Cancer Research Center (DKFZ), 69120, Heidelberg, Germany.
Michael A RiegerGerman Cancer Research Center (DKFZ), 69120, Heidelberg, Germany.
Stefanie GöllnerDepartment of Hematology, Oncology & Rheumatology, University Clinic Heidelberg, 69120, Heidelberg, Germany.
Martin HorstmanDepartment of Pediatric Hematology and Oncology, Research Institute Children's Cancer Center, University Medical Center Hamburg, 20251, Hamburg, Germany.
Martin SchrappeDepartment of Pediatrics, University Hospital Schleswig-Holstein, Campus Kiel, 24105, Kiel, Germany.
Renate Kirschner-SchwabeGerman Cancer Research Center (DKFZ), 69120, Heidelberg, Germany.
Monika BrüggemannDepartment of Hematology and Oncology, University Hospital Schleswig-Holstein, Campus Kiel, 24105, Kiel, Germany.
Carsten Müller-TidowDepartment of Hematology, Oncology & Rheumatology, University Clinic Heidelberg, 69120, Heidelberg, Germany.
Hubert ServeGerman Cancer Research Center (DKFZ), 69120, Heidelberg, Germany.
Altuna AkalinBioinformatics Platform, Berlin Institute for Medical Systems Biology (BIMSB), Max Delbrück Center (MDC), 13125, Berlin, Germany.
Claudia D BaldusDepartment of Hematology and Oncology, Charité, University Hospital Berlin, Campus Benjamin Franklin, 12203, Berlin, Germany. claudia.baldus@uksh.de.
Charité - Universitätsmedizin Berlin · DEGerman Cancer Research Center · DEHeidelberg University · DEDeutschen Konsortium für Translationale Krebsforschung · DEMax Delbrück Center · DEUniversität Hamburg · DEUniversity Hospital Schleswig-Holstein · DEUniversity of Lübeck · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundLong non-coding RNAs (lncRNAs) have emerged as a novel class of RNA due to its diverse mechanism in cancer development and progression. However, the role and expression pattern of lncRNAs in molecular subtypes of B cell acute lymphoblastic leukemia (BCP-ALL) have not yet been investigated. Here, we assess to what extent lncRNA expression and DNA methylation is driving the progression of relapsed BCP-ALL subtypes and we determine if the expression and DNA methylation profile of lncRNAs correlates with established BCP-ALL subtypes.

methodsWe performed RNA sequencing and DNA methylation (Illumina Infinium microarray) of 40 diagnosis and 42 relapse samples from 45 BCP-ALL patients in a German cohort and quantified lncRNA expression. Unsupervised clustering was applied to ascertain and confirm that the lncRNA-based classification of the BCP-ALL molecular subtypes is present in both our cohort and an independent validation cohort of 47 patients. A differential expression and differential methylation analysis was applied to determine the subtype-specific, relapse-specific, and differentially methylated lncRNAs. Potential functions of subtype-specific lncRNAs were determined by using co-expression-based analysis on nearby (cis) and distally (trans) located protein-coding genes.

resultsUsing an integrative Bioinformatics analysis, we developed a comprehensive catalog of 1235 aberrantly dysregulated BCP-ALL subtype-specific and 942 relapse-specific lncRNAs and the methylation profile of three subtypes of BCP-ALL. The 1235 subtype-specific lncRNA signature represented a similar classification of the molecular subtypes of BCP-ALL in the independent validation cohort. We identified a strong correlation between the DUX4-specific lncRNAs and genes involved in the activation of TGF-β and Hippo signaling pathways. Similarly, Ph-like-specific lncRNAs were correlated with genes involved in the activation of PI3K-AKT, mTOR, and JAK-STAT signaling pathways. Interestingly, the relapse-specific lncRNAs correlated with the activation of metabolic and signaling pathways. Finally, we found 23 promoter methylated lncRNAs epigenetically facilitating their expression levels.

conclusionHere, we describe a set of subtype-specific and relapse-specific lncRNAs from three major BCP-ALL subtypes and define their potential functions and epigenetic regulation. The subtype-specific lncRNAs are reproducible and can effectively stratify BCP-ALL subtypes. Our data uncover the diverse mechanism of action of lncRNAs in BCP-ALL subtypes defining which lncRNAs are involved in the pathogenesis of disease and are relevant for the stratification of BCP-ALL subtypes.

Indexed as

AdultBase SequenceBerlinBiomarkers, TumorBone MarrowChildCohort StudiesDNA MethylationEpigenesis, GeneticFemaleHumansMaleMetabolic Networks and PathwaysPrecursor B-Cell Lymphoblastic Leukemia-LymphomaPromoter Regions, GeneticRecurrenceBiomarkers, TumorRNA, Long NoncodingBCP-ALL subtypesDUX4Epigenetically altered lncRNAsKey signaling pathwaysNH-HeHPh-likeRelapse-specific lncRNAsSubtype-specific lncRNAs

Identifiers

PMID30642353
PMCPMC6332539
OpenAlexW2850253353

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.